Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG). Development and validation of machine learning risk prediction ...

Clinical, molecular characteristics, and outcomes of early-onset vs. late-onset colon cancer: A single-center experience. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

A six-month community awareness campaign has significantly increased colorectal cancer awareness in part of Nigeria, leading researchers to recommend expanding the model to the national level.